Close Menu
Chicago News Journal
    Facebook X (Twitter) Instagram
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Facebook X (Twitter) Instagram YouTube TikTok
    Chicago News JournalChicago News Journal
    • Home
    • US News
    • Politics
    • Business
    • Science
    • Technology
    • LifeStyle
    • Music
    • Television
    • Film
    • Books
    • Contact
      • About us
      • Amazon Disclaimer
      • DMCA / Copyrights Disclaimer
      • Privacy Policy
      • Terms and Conditions
    Chicago News Journal
    Home»US News

    FDA approves leucovorin for cerebral folate deficiency but not autism

    AdminBy AdminMarch 10, 2026 US News
    Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram
    FDA approves leucovorin for cerebral folate deficiency but not autism

    The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children. 

    The move comes months after the Trump administration touted leucovorin as a potential therapy for a broader group of patients with autism spectrum disorder symptoms. The claim sparked skepticism among some in the medical and research community, but fueled excitement among families, spiking prescriptions of the drug in the U.S. 

    One FDA official told reporters Monday that “we don’t have sufficient data to say that we could establish efficacy for autism more broadly” but said the agency is open to interest from companies in studying leucovorin in the autism population. 

    The medication, also referred to as folinic acid, is a synthetic form of vitamin B9 that has been used to treat the toxic side effects of chemotherapy. Just a handful of small trials have suggested that leucovorin could be effective as an off-label treatment for children with autism, and some families have reported that it helped their nonverbal kids develop more language and social skills.

    FDA officials, who requested anonymity to discuss the decision, told reporters Monday that they started with a broad review of leucovorin as an autism treatment before narrowing its approval to a smaller population with cerebral folate deficiency, a rare genetic mutation that prevents folate – a key vitamin – from properly reaching the brain. 

    FDA Commissioner Dr. Makary on rare disease therapy approvals, internal politics at the agency

    The condition shares overlapping features with autism, typically develops in young children under age 2 and can cause severe developmental delays, seizures, a lack of muscle control and other serious neurological complications. 

    The officials said the FDA found that using leucovorin in patients with that condition produced the “highest quality data” to support an expanded approval, which will apply to both generic versions of the drug and GSK’s old branded medication, Wellcovorin. 

    “That was the data where we saw the largest effect sizes,” one FDA official said on the call. “So we narrowed in on that population, just because we felt like that was the strongest both scientific rationale and also the largest treatment effects that could be used to then overcome some of the limitations in the data sources.”

    The approval was based on a systematic review of published literature on the area, including patient case reports, but not a randomized controlled clinical trial. The same official acknowledged there can be biases with systematic reviews, but emphasized that the treatment effects were so large that they outweighed those concerns. 

    The FDA is encouraging existing manufacturers of leucovorin to increase production to match higher demand for the drug, the officials added. While GSK originally marketed the drug from 1983 until 1997, the company said in September that it has no plans to relaunch and manufacture the product itself.

    In a release Tuesday, Dr. Tracy Beth Hoeg, acting director of the FDA’s Center for Drug Evaluation and Research, said the approval demonstrates the FDA’s commitment to “rapidly identifying effective treatments for ultra rare diseases while maintaining the same evidentiary standards for approval.”

    Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.

    Read the original article here

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Reddit Telegram

    You might also be interested in...

    Federal Reserve's Cook refuses to participate in White House hearing

    November 17, 2026

    The advice Biden got from Mitt Romney, and other takeaways from his memoir

    November 17, 2026

    Lindsay Clancy gets new trial date

    November 16, 2026

    Apple launches an AI health tool as part of a research study

    November 16, 2026

    Pope crosses Peru in finale of trip home to visit flock high in Andes, deep in Amazon

    November 15, 2026

    How travelers can navigate trips as ground stop effects linger, expert says

    November 15, 2026
    Popular Posts

    Cybersecurity AI startup Corma reaches $1B valuation in about 3 months | TechCrunch

    Miley Cyrus Shares Sweet Memory of Godmother Dolly Parton as They Earn a Grammy Nod Together

    Two Pianos, Four Hands, One Thunderstorm: Avohee Avoher’s “Caelune” Is a Dark and Dazzling Triumph

    'The Odyssey' Interview: Christopher Nolan and Matt Damon

    Lindsay Clancy gets new trial date

    Ali Hazelwood Sparks Discourse About White Authors Writing Black Characters

    Categories
    • Books (2,453)
    • Business (3,447)
    • Events (34)
    • Film (1,058)
    • LifeStyle (2,919)
    • Music (2,792)
    • Politics (2,355)
    • Science (1,948)
    • Technology (1,813)
    • Television (3,624)
    • US News (3,291)
    Archives
    Useful Links
    • Contact us
    • About us
    • Amazon Disclaimer
    • DMCA / Copyrights Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Popular Posts
    • Rocky Kramer’s Rock & Roll Tuesdays Presents “Armageddon” June 13th, 2023, 7 PM PT on TwitchRocky Kramer’s Rock & Roll Tuesdays Presents “Armageddon” June 13th, 2023, 7 PM PT on Twitch
    • Homeless Baby Boomers By Howard BloomHomeless Baby Boomers By Howard Bloom
    • Every Muppets TV Show Ranked From Worst to BestEvery Muppets TV Show Ranked From Worst to Best
    • Pharrell Williams Carries Torch at Paris 2024 OlympicsPharrell Williams Carries Torch at Paris 2024 Olympics
    • Forest Swords Announces First Album Since 2017, Shares New Video: Watch
    Archives
    Categories
    • Books
    • Business
    • Events
    • Film
    • LifeStyle
    • Music
    • Politics
    • Science
    • Technology
    • Television
    • US News
    Facebook X (Twitter) Instagram YouTube TikTok
    © 2026 Chicago News Journal. All rights reserved. All articles, images, product names, logos, and brands are property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Terms of Use and Privacy Policy.

    Type above and press Enter to search. Press Esc to cancel.